Tier 4 — mechanistic

Plasma choline and betaine and neurological function trajectory after acute ischemic stroke

Zhiyi Zong, Churan Zhou, Heping Guo, Mengyue Cao, Suyang Wu, Tan Xu, Yonghong Zhang, Chongke Zhong, Huihui Liu
BMC neurology 2026 26(1):586

Bibliography

PubMed
PMID 42374230
PubMed Central
PMC13579963
DOI
10.1186/s12883-026-05132-9
Funding
Reported funding/support: https://doi.org/10.13039/501100001809National Natural Science Foundation of China82571501LiuHuihui GuSu Talent ProgramGSWS2022031LiuHuihui
Competing interests
Reported disclosure: Declarations. Ethics approval and consent to participate: The data used for analysis and collection came from previously published studies that had acquired ethical approval. Ethical approval was not required for this evaluation. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Study snapshot

DesignProspective post-stroke cohort analysis
ModelHuman participants
Sample933 ischemic-stroke patients
InterventionMeasured betaine status and related metabolites; no randomized TMG treatment
DurationFollow-up through 24 months
EndpointsPost-stroke neurological function

What the study showed, in plain terms

Published in 2026, this source examined human observational and biomarker research. It examined Measured betaine status and related metabolites; no randomized TMG treatment. The source describes 933 ischemic-stroke patients.

Lower baseline betaine was associated with less favorable neurological-recovery trajectories.

Observational exposure analysis: residual confounding and reverse causation remain possible. Associations do not establish that betaine supplementation causes the same outcome.

Continue with TMG Data Center

Continue with TMG and Blood Pressure: What Human Studies Show

Key findings

  • Lower baseline betaine was associated with less favorable neurological-recovery trajectories.
  • The recorded outcome domains were Post-stroke neurological function.

What this study can and cannot tell us

  • Observational exposure analysis: residual confounding and reverse causation remain possible. Associations do not establish that betaine supplementation causes the same outcome.
  • Source basis: Accessible full-text extract plus indexed bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Betaine: A Promising Natural Product for Neurological and Psychiatric Diseases
Ying Zhang et al. · Current neuropharmacology · 2026
Tier 4
Association of trimethylamine oxide and its precursors with cognitive impairment: a systematic review and meta-analysis
Caiyi Long et al. · Frontiers in aging neuroscience · 2024
Tier 2
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients
D Knopman et al. · Alzheimer disease and associated disorders · 2001
Tier 4
Global DNA hypomethylation and its correlation to the betaine level in peripheral blood of patients with schizophrenia
Yui Murata et al. · Progress in neuro-psychopharmacology & biological psychiatry · 2020
Tier 4
Dietary Choline and Betaine and Risk of CVD: A Systematic Review and Meta-Analysis of Prospective Studies
Katie A Meyer et al. · Nutrients · 2017
Tier 4
Dietary Choline and Betaine Are Not Associated With the Risk of Type 2 Diabetes. A Systematic Review and Meta-Analysis of Observational Studies
Elham Sharifi-Zahabi et al. · Journal of diabetes research · 2026

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology